Table 1.
Association between expression of p-eIF4E, β-catenin, MMP-7, cyclin D1 and c-Myc proteins and NPC clinical pathological features (N= 163)
| Characteristics(n) | p-eIF4E | β-catenin | MMP-7 | cyclinD1 | c-Myc | p-eIF4E/β-catenin/MMP-7/cyclinD1/c-Myc* | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | P | Normal (%) | Abnormal (%) | P | Low (%) | High (%) | P | Low (%) | High (%) | P | N (%) | P (%) | P | N- (%) | P+ (%) | P | |
| Age(yr) | ||||||||||||||||||
| ≤40(n=58) | 14(24.1) | 44(75.9) | 0.143 | 19(32.8) | 39(67.2) | 0.274 | 28(48.3) | 30(51.7) | 0.071 | 35(60.3) | 23(39.7) | 0.607 | 33(56.9) | 25(43.1) | 0.700 | 52(89.7) | 6(10.3) | 0.301a |
| >40(n=105) | 37(35.2) | 68(64.8) | 26(24.8) | 79(75.2) | 66(62.9) | 39(37.1) | 59(56.2) | 46(43.8) | 63(60.0) | 42(40.0) | 100(95.2) | 5(4.8) | ||||||
| Gender | ||||||||||||||||||
| Female(n=36) | 15(41.7) | 21(58.3) | 0.128 | 14(38.9) | 22(61.1) | 0.086 | 25(69.4) | 11(30.6) | 0.105 | 22(61.1) | 14(38.9) | 0.636 | 20(55.6) | 16(44.4) | 0.644 | 33(91.7) | 3(8.3) | 0.958a |
| Male(n=127) | 36(28.3) | 91(71.7) | 31(24.4) | 96(75.6) | 69(54.3) | 58(45.7) | 72(56.7) | 55(43.3) | 76(59.8) | 51(40.2) | 119(93.7) | 8(6.3) | ||||||
| Histological type | ||||||||||||||||||
| DNC(n=14) | 6(42.9) | 8(57.1) | 0.500a | 4(28.6) | 10(71.4) | 1.000a | 8(57.1) | 6(42.9) | 0.967 | 5(35.7) | 9(64.3) | 0.082 | 10(71.4) | 4(28.6) | 0.319 | 14(100.0) | 0(0.0) | 0.601b |
| UDNC(n=149) | 45(30.2) | 104(69.8) | 41(27.5) | 108(72.5) | 86(57.7) | 63(42.3) | 89(59.7) | 60(40.3) | 86(57.7) | 63(42.3) | 138(92.6) | 11(7.4) | ||||||
| Clinical Stages | ||||||||||||||||||
| StagesⅠ-Ⅱ(n=67) | 22(32.8) | 45(67.2) | 0.722 | 34(50.7) | 33(49.3) | <0.001* | 48(71.6) | 19(28.4) | 0.003* | 48(71.6) | 19(28.4) | 0.003* | 39(58.2) | 28(41.8) | 0.882 | 64(95.5) | 3(4.5) | 0.517a |
| Stages Ⅲ-Ⅳ(n=96) | 29(30.2) | 67(69.8) | 11(11.5) | 85(88.5) | 46(47.9) | 50(52.1) | 46(47.9) | 50(52.1) | 57(59.4) | 39(40.6) | 88(91.7) | 8(8.3) | ||||||
| LN Status | ||||||||||||||||||
| LNM(n=105) | 33(31.4) | 72(68.6) | 0.959 | 12(11.4) | 93(88.6) | <0.001* | 52(49.5) | 53(50.5) | 0.005* | 53(50.5) | 52(49.5) | 0.012* | 60(57.1) | 45(42.9) | 0.541 | 99(94.3) | 6(5.7) | 0.702a |
| No LNM(n=58) | 18(31) | 40(69) | 33(56.9) | 25(43.1) | 42(72.4) | 16(27.6) | 41(70.7) | 17(29.3) | 36(62.1) | 22(37.9) | 53(91.4) | 5(8.6) | ||||||
| Survival Status | ||||||||||||||||||
| Alive(n=79) | 29(36.7) | 50(63.3) | 0.148 | 42(53.2) | 37(46.8) | <0.001* | 59(74.7) | 20(25.3) | <0.001* | 62(78.5) | 17(21.5) | <0.001* | 53(67.1) | 26(32.9) | 0.039* | 77(97.5) | 2(2.5) | 0.037* |
| Dead(n=84) | 22(26.2) | 62(73.8) | 3(3.6) | 81(96.4) | 35(41.7) | 49(58.3) | 32(38.1) | 52(61.9) | 43(51.2) | 41(48.8) | 75(89.3) | 9(10.7) | ||||||
Abbreviations:
DNC: Differentiated non-keratinized nasopharyngeal carcinoma, UDNC: Undifferentiated non-keratinized nasopharyngeal carcinoma, LN: lymph node. n, Number of cases
*: statistically significant (p < 0.05), statistical analysis was performed using the Chi-squared test.
+: Common positive staining of five proteins, _: any negative expression of five proteins.
a: Continuity correction of Chi-squared-value
b: DNC versus UDNC, Fisher's exact test